Avalyn Pharma (AVLN) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Avalyn Pharma is the larger company by market cap ($1.13 billion vs $1.11 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVLN | VOR |
|---|---|---|
| Share price | $25.53 | $18.78 |
| Market cap | $1.13B | $1.11B |
| 1-day change | +0.39% | +2.57% |
| YTD return | — | +43.58% |
| 1-year return | — | -44.44% |
| 5-year return | — | -93.93% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-2.47 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.17 | $33.50 |
| 52-week low | $24.15 | $6.50 |
| Distance from 52-week high | -36.45% | -43.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +142.07% | +107.67% |
| Average volume | 234.81K | 992.56K |
| Shares outstanding | 44.33M | 59.16M |
| Employees | 55 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalyn Pharma
AVLN stock →Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
AVLN vs VOR FAQ
Which is bigger, Avalyn Pharma or Vor Biopharma?
Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.13B compared with $1.11B for Vor Biopharma (VOR).
Are Avalyn Pharma and Vor Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Avalyn Pharma and Biotechnology: Biological Products (No Diagnostic Substances) for Vor Biopharma.